Skip to main content
. Author manuscript; available in PMC: 2019 Jan 1.
Published in final edited form as: Immunohorizons. 2018 Jan 1;2(1):54–66. doi: 10.4049/immunohorizons.1700069

FIGURE 3. MR1-TM does not inhibit the development of ATD and pSS in mice lacking the PD-1 inhibitory molecule.

FIGURE 3

(A) The experimental design is identical to that in Fig. 1A. Mice were 17–20 wk old when thyroids were removed. Isotype control (n = 18) versus MR1 (n = 19): **p < 0.001 for females, isotype control (n = 18) versus MR1 (n = 19). *p < 0.05 for males. (B) Representative H&E-stained sections of thyroids from a mouse given isotype control or MR1. ATD severity scores are 4+, isotype control; 5+, MR1. Original magnification ×100. (C) Salivary gland focus scores (foci per four square millimeters) of some mice from (A). There are no significant differences between isotype controls and MR1-treated mice. Female mice have more severe pSS than males. (D) Representative H&E-stained sections of salivary glands of a female mouse given isotype control or MR1. Scale bars, 1 mm.